secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016489
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q2 net loss $16M; positive RT-102 Phase 1 results
-------------------------------------------------------------------

- Positive Phase 1 topline results for RT-102 (PTH capsule for osteoporosis): high bioavailability, well-tolerated, all endpoints met.
- Completed debt financing up to $45M with Avenue Capital Group; $15M funded at closing; cash runway extended into mid-2024.
- Cash and equivalents $97.2M at June 30, 2022 vs $117.5M at Dec 31, 2021.
- Net loss of $16.0M in Q2 2022 vs $5.5M in Q2 2021; R&D expenses rose to $9.5M.
- Near-term milestones: repeat-dose RT-102 results in Q4 2022, additional Phase 1 trial initiation in 2H 2022, pre-IND meeting with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/0000950170-22-016489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/rani-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer